DJIA 16,805.41 127.51 0.76%
NASDAQ 4,483.72 30.92 0.69%
S&P 500 1,964.58 13.76 0.71%
market minute promo

Alkermes, Inc. (NASDAQ: ALKS)

45.91 0.63 (1.39%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ALKS $45.91 1.39%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $45.57
Previous Close $45.28
Daily Range $45.27 - $46.39
52-Week Range $34.28 - $54.25
Market Cap $6.7B
P/E Ratio -1,509.33
Dividend (Yield) $0.00 (0.0%)
Volume 760,917
Average Daily Volume 977,161
Current FY EPS -$0.25

Sector

Healthcare

Industry

Drugs

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

News & Commentary Rss Feed

Is Alkermes plc Stock Undervalued?

Strong science and underserved markets can fuel further gains from this delivery-focused biopharma

Bank Of America Q3 Small & Mid-Cap Biotech Preview

5 Stocks That Will See Big Selling on Huge ETF Rebalance

3 Likely Biotech Buyout Candidates

ALKS Crosses Above Key Moving Average Level

Cramer's Lightning Round - Edwards LifeSciences Is The Hottest Game In Town (9/15/14)

'Mad Money' Lightning Round: Buy, Buy, Buy St Jude Medical

First Week of October 18th Options Trading For Alkermes (ALKS)

Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog

Credit Suisseā€™s 4 Top Pharmaceutical Stocks to Buy for the Rest of 2014

Alkermes Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Sp

Alkermes Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic

See More ALKS News...

ALKS's Top Competitors

ALKS $45.91 (1.39%)
Current stock: ALKS
CELG $103.24 (2.83%)
Current stock: CELG
AMGN $147.26 (0.01%)
Current stock: AMGN
BIIB $321.67 (1.77%)
Current stock: BIIB